Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs in R&D
Erschienen in: Drugs in R&D 6/2006

01.11.2006 | Adis R&D Profile

Methylnaltrexone

MNTX

Erschienen in: Drugs in R&D | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Excerpt

Methylnaltrexone is a peripheral opioid receptor antagonist undergoing phase III clinical trials for the treatment of opioid-induced constipation in patients with advanced medical illness who are being treated with narcotics for pain. The compound does not cross the blood-brain barrier in humans and reverses the opioid effects without interfering with pain relief. Some opioid-induced adverse events that the drug may potentially target include constipation, nausea/vomiting, cough suppression and urinary retention. Methylnaltrexone was discovered by researchers at the University of Chicago, Chicago, Illinois, USA and is in joint development with Progenics Pharmaceuticals and Wyeth Pharmaceuticals. …
Literatur
1.
Wyeth Pharmaceuticals, Progenics Pharmaceuticals Inc. Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone; Methylnaltrexone in Late-Stage Clinical Development for Opioid-Induced Constipation and Post-Operative Bowel Dys-function. Media Release: 23 Dec 2005. Available from URL: http://​www.​wyeth.​com
2.
Progenics Pharmaceuticals Inc. Progenics Acquires Methylnaltrexone Rights from Licensors and Plans to File Shelf Registrations. Media Release: 23 Dec 2005. Available from URL: http://​www.​progenics.​com
3.
Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock. Media Release: 1 Apr 2005. Available from URL: http://​www.​p-rogenics.​com
4.
Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation; All Primary and Secondary Efficacy Endpoints Were Highly Statistically Significant. Media Release: 15 Feb 2006. Available from URL: http://​www.​progenics.​com
5.
Progenics Pharmaceuticals Inc. Progenics Initiates Second Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation. Media Release: 13 Jan 2004. Available from URL: http://​www.​progenics.​com
6.
Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Second Pivotal Phase 3 Clinical Trial of Methylnal-trexone for Opioid-Induced Constipation. Media Release: 30 Sep 2005. Available from URL: http://​www.​progenics.​com
7.
Progenics Pharmaceuticals Inc. CORRECTING and REPLACING Progenics Announces Positive Top-Line Results from Pivotal Phase 3 Clinical Trial of methylnaltrexone in Opioid-Induced Constipation. Media Release: 10 Mar 2005. Available from URL: http://​www.​progenics.​com
8.
Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Pivotal Phase 3 Clinical Trial of Methylnaltrexone for Opioid-Induced Constipation. Media Release: 3 Dec 2004. Available from URL: http://​www.​progenics.​com
9.
Wyeth Pharmaceuticals, Progenics Pharmaceuticals. Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus. Media Release: 17 Jul 2006. Available from URL: http://​www.​wy-eth.​com
10.
Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Phase 2 Clinical Trial of methylnaltrex-one in Post-Operative Bowel Dysfunction. Media Release: 20 Jan 2005. Available from URL: http://​www.​progenics.​com
11.
Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Successfully Completes Two, Phase 1 Clinical Studies of Oral Methylnaltrexone. Media Release: 25 May 2004. Available from URL: http://​www.​progenics.​com
12.
Progenics Pharmaceuticals Inc. Progenics Initiates Methylnaltrexone Phase-3 Clinical Program for Opioid-Induced Constipation; Positive Phase-2 Trial in Hospice Patients Provides Basis for Pivotal Study. Media Release: 20 Dec 2002. Available from URL: http://​www.​progenics.​com
13.
Progenics Pharmaceuticals Inc. Progenics Reports Methylnaltrexone Activity in Reversing Opioid-Induced Urinary Retention. Media Release: 10 Oct 2003. Available from URL: http://​www.​progenics.​com
14.
Progenics Pharmaceuticals Inc. Progenics initiates phase 2 clinical trial of methylnaltrexone to treat post-operative ileus. Media Release: 13 May 2003. Available from URL: http://​www.​progenics.​com
ai]15.
Yuan C-S, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA: the Journal of the American Medical Association 283: 367–372, 19 Jan 2000CrossRef
16.
Progenics Pharmaceuticals Inc. Progenics announces results from methylnaltrexone phase 2 clinical trial in opioid-induced constipation. Media Release: 30 Apr 2003. Available from URL: http://​www.​progenics.​com
Metadaten
Titel
Methylnaltrexone
MNTX
Publikationsdatum
01.11.2006
Verlag
Springer International Publishing
Erschienen in
Drugs in R&D / Ausgabe 6/2006
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI
https://doi.org/10.2165/00126839-200607060-00006

Weitere Artikel der Ausgabe 6/2006

Drugs in R&D 6/2006 Zur Ausgabe

Review Article

A Chaperone-Mediated Approach to Enzyme Enhancement as a Therapeutic Option for the Lysosomal Storage Disorders

Adis R&D Profile

Telavancin

Adis R&D Profile

Oregovomab

Review Article

Gliquidone Contributes to Improvement of Type 2 Diabetes Mellitus Management

Acknowledgments

Acknowledgement

Adis R&D Profile

Etravirine